Moreover, combined treatment with imatinib and miR-30a increased drug sensitivity in chronic myeloid leukemia cells through regulation of ATG5 and BECN1/Beclin 1 (65). This evidence concerns the gene BECN1 and chronic myelogenous leukemia, BCR-ABL1 positive.